Status:
WITHDRAWN
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Conditions:
Glioma of Brain
CAR-T Cell Immunotherapy
Eligibility:
All Genders
30-70 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
Detailed Description
Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with co...
Eligibility Criteria
Inclusion
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies after cancer recurrence
- Body tumor 1-6, the maximum tumor length \< 2 cm
- KPS ≥ 70, lifespan \> 6 months
- Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Key Trial Info
Start Date :
September 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04406610
Start Date
September 1 2015
End Date
October 15 2016
Last Update
July 16 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.